The Vdr: Why Your Vitamin D3 Might Not Be Protecting Your Ageing Brain
Quick Read Vitamin D does more than support bones. It acts as a signalling molecule that switches genes on and
We write a new article on supplements every day , all detailed, with citations.
Once a week we send an email containing a list of the last 7 days articles. Please sign up and also feel free to share the articles with friends and family who you think might benefit.
Simon Parrott – Vitacuity Ltd
Magnesium L-threonate is a special form of magnesium designed to cross the blood-brain barrier, the protective membrane that blocks most magnesium supplements from reaching your brain. Once inside, it supports the connections between brain cells, increases the number of these connections, and may help protect against age-related memory loss and damage from Alzheimer’s disease. Fifteen years of animal research consistently shows benefits for memory, learning, and brain cell growth.
The catch is that almost all this evidence comes from studies in rodents and mice with Alzheimer’s-like disease. Only one human trial exists so far, published in 2022, which found improvements in cognitive outcomes but with limited detail available. While the biological mechanism is well-understood and encouraging, we don’t yet know if these impressive animal results translate to real benefit in people or what the optimal human dose should be.
Magnesium itself is safe and deficiency is common in modern diets. Magnesium L-threonate’s ability to actually reach the brain gives it a theoretical advantage over standard magnesium supplements for brain health. However, this is not a proven treatment for Alzheimer’s or any disease, and the human evidence is too early to make strong claims.
Verdict: Magnesium L-threonate has compelling biological plausibility and promising preclinical research, but meaningful human evidence is still limited, so consider it a potentially worthwhile brain health option rather than an established solution.
What if the reason your memory feels less sharp in your 40s and 50s isn’t simply “getting older”, but rather a very specific, measurable loss happening at the microscopic connections between your brain cells? And what if a particular form of magnesium, one engineered specifically to cross into the brain, could help rebuild and protect those connections?
These are the questions researchers have been asking for the better part of fifteen years. Vitacuity has read over 1.77 million research papers and selected the most relevant ones on this topic. What we found is genuinely interesting, and honestly, more complicated than the supplement industry usually admits. Magnesium L-threonate (MgT) has a compelling and growing body of research behind it, almost all of it in animal models so far, with one notable human trial now in the mix. Here is an honest, complete picture of what the science actually shows.
To understand why MgT is different from the magnesium in your average supplement, you need to understand the brain’s border control system. Your brain is protected by something called the blood-brain barrier, a highly selective membrane that keeps most substances out, including most forms of supplemental magnesium. Standard magnesium citrate, oxide, or sulphate raises magnesium levels in the blood and body, but very little crosses into the brain itself.
Magnesium L-threonate was specifically designed to solve this problem. The threonate molecule, derived from vitamin C metabolism, acts as a kind of carrier, ferrying magnesium across the blood-brain barrier and raising actual magnesium concentrations inside the brain [2]. This distinction matters enormously, because magnesium inside the brain plays a very specific and critical role.
At the heart of this story is something called the NMDA receptor. These are protein structures on the surface of brain cells that act as the gatekeepers of learning and memory. When two brain cells communicate in a coordinated, repeated way, the kind of activity that happens when you’re learning something new, NMDA receptors open and allow a cascade of signals that physically strengthen the connection between those cells. This process is called synaptic plasticity, and it’s the cellular foundation of memory itself.
Magnesium sits right at the centre of this process. It regulates NMDA receptor function, influences synapse density (how many connections exist between brain cells), and appears to modulate the expression of a specific subunit of the NMDA receptor called NR2B, which is particularly important for learning and memory [3]. As we age, NR2B levels naturally decline in the brain, and with them, some of our capacity for sharp, flexible cognition [3]. The working hypothesis behind MgT is straightforward: if we can get more magnesium into the brain, we can protect and potentially restore the infrastructure of memory.
That’s the mechanism. Now let’s look at what the research actually shows.
The foundational paper in this field came from MIT researchers in 2010, published in the journal *Neuron* [2]. The team developed MgT specifically to elevate brain magnesium and tested it extensively in rats, both young and aged.
The results were striking. MgT-treated rats showed improvements in working memory, short-term memory, and long-term memory compared to controls [2]. But the more remarkable finding was what the researchers saw when they looked at the brain tissue directly. Rats given MgT had a higher density of synaptophysin- and synaptobrevin-positive puncta, essentially, more functional synaptic connection points, in the hippocampus, the brain region most critical for memory formation [2].
At the functional level, magnesium increased the number of active presynaptic release sites while simultaneously fine-tuning how readily signals were released. The net result was a synaptic configuration that was better suited to processing the kind of coordinated, burst-like activity that encodes memories [2]. NR2B-containing NMDA receptors were upregulated, and long-term potentiation, the synaptic strengthening process that underlies learning, was enhanced [2].
Evidence grade: Early stage / Promising. This is animal research, rats, not humans. But the mechanistic detail is unusually thorough, and this study established the biological plausibility that underpins everything that followed.
Once the basic mechanism was established, researchers turned their attention to a harder question: could MgT protect synapses in the context of active neurodegenerative disease?
Two closely related studies, published in 2013 and 2014, tested this using APPswe/PS1dE9 mice, a standard transgenic model of Alzheimer’s disease in which mice develop amyloid plaques and cognitive decline that broadly mirrors the early features of the human disease [4][5].
Both studies found that MgT treatment reduced amyloid-beta plaque burden, prevented synapse loss, and reversed cognitive deficits in these mice [4][5]. Crucially, the synapse loss, which is considered one of the strongest predictors of cognitive decline in Alzheimer’s disease, was substantially arrested by MgT treatment [4].
The molecular story was detailed. In untreated AD mice, the NMDA receptor signalling pathway was suppressed, and an enzyme called BACE1, which drives the production of amyloid-beta, was overactivated. MgT treatment normalised both of these processes, reducing the production of toxic amyloid fragments and restoring NMDA receptor signalling [4][5]. A key mechanism appeared to be MgT’s ability to prevent overactivation of a protein called calcineurin, which was stripping NMDA receptors from synaptic connections in the presence of high amyloid-beta [5].
Perhaps the most provocative finding: MgT was effective even when treatment began at the end stage of the AD-like pathology in these mice, suggesting the intervention may retain value even when disease is already established, not just as prevention [4][5].
Evidence grade: Early stage. These are impressive findings in a well-validated mouse model, but mouse models of Alzheimer’s are notoriously imperfect predictors of human outcomes. This research tells us the mechanism is biologically plausible and that effects are reproducible, it does not tell us MgT works in human Alzheimer’s disease.
A 2016 study added another dimension to the MgT story that most people in the supplement space completely overlook [11]. Researchers found that MgT didn’t just protect existing synapses, it appeared to stimulate the growth of entirely new brain cells.
The adult brain retains a small population of neural stem cells, primarily in a region of the hippocampus called the sub-granular zone. These stem cells can divide and produce new neurons, a process called adult neurogenesis, though this capacity declines with age. The 2016 study found that MgT supplementation in both young and aged mice significantly increased the number of hippocampal neural stem cells and enhanced their rate of proliferation [11].
Strikingly, in mice that received MgT supplementation for twelve months, the age-associated decline in neural stem cell activity was curtailed, without depleting the stem cell reservoir itself [11]. In laboratory cultures, elevated magnesium concentrations were sufficient to promote neural stem cell self-renewal, suggesting the effect is direct [11].
This finding was replicated and extended in a 2025 study published in *Experimental Neurobiology*, which used Alzheimer’s model mice and found that MgT improved cognitive performance by stimulating the generation of new neurons in the hippocampus, specifically via activation of ERK and CREB signalling pathways, which are master regulators of neuronal growth and survival [1].
Evidence grade: Early stage. All neurogenesis research in this area is animal-based. Human adult neurogenesis itself remains a contested topic in neuroscience, which adds a layer of uncertainty here.
Some of the most intriguing MgT findings have nothing to do with Alzheimer’s disease. A series of studies between 2011 and 2013 explored how elevating brain magnesium affected fear memory, anxiety-related learning, and a cognitive ability called pattern separation.
A 2011 study found that MgT treatment in rats enhanced synaptic plasticity in the prefrontal cortex, specifically in a region called the infralimbic cortex, which improved the animals’ ability to extinguish (essentially unlearn) fear memories without erasing the original memory itself [7]. This regional specificity was notable: MgT boosted plasticity in the prefrontal cortex but not in the amygdala (the brain’s fear centre), which the researchers suggested might make it useful for enhancing cognitive therapy for anxiety disorders without blunting the emotional learning system [7].
A 2013 study extended this to spatial memory and pattern separation [6]. Pattern separation is the brain’s ability to tell apart two similar-but-different experiences, encoding them as distinct memories rather than blurring them together. This capacity is also hippocampus-dependent and declines with age. MgT-treated rats showed significantly improved ability to discriminate between similar contexts and were less prone to fear overgeneralisation, the tendency to respond fearfully to situations that merely resemble a threatening one [6].
A parallel 2013 study confirmed that MgT sped up the extinction of conditioned taste aversions and reduced spontaneous relapse of the learned aversion [9], further supporting the idea that elevated brain magnesium enhances the brain’s capacity for adaptive forgetting, not just memory formation.
Evidence grade: Early stage. Fascinating mechanistic work in animal models, with real potential implications for anxiety and age-related cognitive flexibility. Human trials in this area do not yet exist.
Here is where we must be very honest with you. The vast majority of MgT research is in animals. There is one human randomised controlled trial in the research we reviewed, published in *Nutrients* in 2022, testing a branded form of MgT called Magtein [15].
The trial was conducted in an East Asian adult population and used a double-blind design, the gold standard for clinical evidence. The study found that MgT supplementation improved cognitive outcomes in participants, with the threonate form demonstrating superior bioavailability compared to other magnesium compounds [15].
However, the study details are limited in what was shared in the available abstract. We cannot report precise effect sizes, sample sizes, or the full scope of cognitive domains tested without access to the full paper. What we can say is that this represents the first human RCT data on MgT and cognition, and the direction of effect is consistent with the animal literature.
Evidence grade: Promising, but only one human trial, and with limited detail available on sample size and duration. More human research is urgently needed before firm conclusions can be drawn.
One additional study is worth noting. A 2019 study in mice tested whether MgT could protect dopamine neurons against damage induced by MPTP, a compound that causes Parkinson’s-like neurodegeneration [13]. MgT significantly elevated magnesium levels in the cerebrospinal fluid, reduced dopamine neuron loss, and improved motor deficits compared to mice given conventional magnesium sulphate, which failed to meaningfully raise brain magnesium levels [13].
This is very preliminary, animal research only, but it suggests that MgT’s ability to cross the blood-brain barrier may make it relevant across a broader range of neurodegenerative conditions than Alzheimer’s disease alone [13].
Evidence grade: Early stage.
Let’s be direct about the gaps, because they are significant.
The human trial gap is the biggest issue. Almost everything compelling about MgT, the synaptic density findings, the neurogenesis data, the Alzheimer’s protection results, comes from animal studies. Mice and rats are not humans. The Alzheimer’s mouse model in particular has a poor track record of predicting outcomes in human clinical trials. Treatments that worked brilliantly in these mice have repeatedly failed in human patients.
We don’t know the optimal human dose. Animal studies use doses that don’t translate directly to human equivalents, and the one human trial doesn’t provide sufficient detail in the available data to give us strong dose guidance.
We don’t know long-term safety in humans. MgT appears safe at normal doses based on what we know about magnesium generally, but long-term human data specifically for MgT is thin.
The pattern separation and fear extinction findings are interesting but entirely preclinical. We don’t yet know whether these effects, which could be genuinely meaningful for anxiety disorders or age-related cognitive decline, translate to humans at all.
We don’t know who benefits most. Is MgT more useful for people who are already magnesium-deficient? For those with early cognitive decline? For healthy older adults trying to maintain function? The animal research doesn’t answer this, and the one human trial is not large enough to stratify by these variables.
The Alzheimer’s findings, while compelling in mice, remain speculative in humans. We are not claiming MgT treats or prevents Alzheimer’s disease in humans. The mouse data is mechanistically fascinating and worthy of serious investigation, but it is not clinical evidence.
Here’s how a sensible, informed person should think about MgT in 2025.
The mechanism is genuinely compelling. The idea that a specific form of magnesium can cross the blood-brain barrier, increase synapse density, support neural stem cell activity, upregulate NR2B receptors, and protect against amyloid-related damage is not hand-waving, it’s supported by fifteen years of consistent animal research, a defined molecular pathway, and now a first human trial pointing in the same direction. That is more than most supplement ingredients can claim.
But we’re not there yet with humans. The honest position is this: the preclinical case is strong enough to take seriously, the human evidence is early but encouraging, and the safety profile of magnesium generally is excellent at normal doses.
Magnesium is a water-soluble mineral at physiological doses and excess is excreted, it’s one of the safer supplements you can take. Genuine magnesium deficiency is common in adults eating a modern Western diet, and deficiency itself has real cognitive consequences. That baseline case for supplementation is solid regardless of the MgT-specific research.
If you’re specifically interested in MgT for brain health, the typical doses used in human research are in the range studied under the Magtein brand. Magnesium is generally well-tolerated; the main side effect of excessive magnesium supplementation is digestive discomfort.
Our practical suggestions:
– If you’re already taking a general magnesium supplement for sleep, muscle function, or general health, the evidence supports continuing, magnesium deficiency is common and the benefits of adequate levels are well-established across many systems. – If you’re specifically interested in brain health and cognitive support, MgT’s superior blood-brain barrier penetration gives it a mechanistic advantage over standard magnesium forms that is biologically meaningful, even if the human trial evidence is still early. – Don’t expect miracles. MgT is not a treatment for Alzheimer’s disease. It is a biologically plausible brain health intervention with a promising but still-developing evidence base. – Pair it with the fundamentals. The 2018 study found that MgT combined with environmental enrichment, stimulating environments, learning new things, social engagement, had a synergistic effect on memory in AD mice [8]. The supplement story and the lifestyle story are not in competition.
Watch this space. The human trials, when they come in larger numbers, will tell us whether fifteen years of animal research translates to real-world human benefit. The mechanism is there. The first human signals are encouraging. The risk of supplementing at normal doses is low. That’s a reasonable basis for a considered decision, made with eyes open to what we know and what we still don’t.
[1] Magnesium-L-threonate Ameliorates Cognitive Deficit by Attenuating Adult Hippocampal Neurogenesis Impairment in a Mouse Model of Alzheimer’s Disease (2025). *Experimental Neurobiology*. DOI: 10.5607/en24030 | https://pubmed.ncbi.nlm.nih.gov/40234095/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12069926/
[2] Enhancement of Learning and Memory by Elevating Brain Magnesium (2010). *Neuron*. https://pubmed.ncbi.nlm.nih.gov/20152124/
[3] Targeting the NMDA Receptor Subunit NR2B for Treating or Preventing Age-Related Memory Decline (2014). *Expert Opinion on Therapeutic Targets*. DOI: 10.1517/14728222.2014.941286 | https://pubmed.ncbi.nlm.nih.gov/25152202/
[4] Elevation of Brain Magnesium Prevents Synaptic Loss and Reverses Cognitive Deficits in Alzheimer’s Disease Mouse Model (2014). *Molecular Brain*. DOI: 10.1186/s13041-014-0065-y | https://pubmed.ncbi.nlm.nih.gov/25213836/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172865/
[5] Elevation of Brain Magnesium Prevents and Reverses Cognitive Deficits and Synaptic Loss in Alzheimer’s Disease Mouse Model (2013). *Journal of Neuroscience*. https://pubmed.ncbi.nlm.nih.gov/23658180/
[6] Magnesium Supplement Enhances Spatial-Context Pattern Separation and Prevents Fear Overgeneralization (2013). *Behavioural Brain Research*. https://pubmed.ncbi.nlm.nih.gov/23764903/
[7] Effects of Elevation of Brain Magnesium on Fear Conditioning, Fear Extinction, and Synaptic Plasticity in the Infralimbic Prefrontal Cortex and Lateral Amygdala (2011). *Journal of Neuroscience*. https://pubmed.ncbi.nlm.nih.gov/22016520/
[8] Magnesium Boosts the Memory Restorative Effect of Environmental Enrichment in Alzheimer’s Disease Mice (2018). *CNS Neuroscience & Therapeutics*. DOI: 10.1111/cns.12775 | https://pubmed.ncbi.nlm.nih.gov/29125684/
[9] Chronic Dietary Magnesium-L-Threonate Speeds Extinction and Reduces Spontaneous Recovery of a Conditioned Taste Aversion (2013). *Behavioural Processes*. https://pubmed.ncbi.nlm.nih.gov/23474371/
[10] Neurobehavioral and Biochemical Effects of Magnesium Chloride (MgCl2), Magnesium Sulphate (MgSO4) and Magnesium-L-Threonate (MgT) Supplementation in Rats: A Dose Dependent Comparative Study (2019). *Pakistan Journal of Pharmaceutical Sciences*. https://pubmed.ncbi.nlm.nih.gov/30829204/
[11] Elevation of Brain Magnesium Potentiates Neural Stem Cell Proliferation in the Hippocampus of Young and Aged Mice (2016). *Journal of Cellular Physiology*. https://pubmed.ncbi.nlm.nih.gov/26754806/
[13] Treatment of Magnesium-L-Threonate Elevates the Magnesium Level in the Cerebrospinal Fluid and Attenuates Motor Deficits and Dopamine Neuron Loss in a Mouse Model of Parkinson’s Disease (2019). *Neuropsychiatric Disease and Treatment*. DOI: 10.2147/NDT.S230688 | https://pubmed.ncbi.nlm.nih.gov/31806980/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857673/
[14] By Suppressing the Expression of Anterior Pharynx-Defective-1α and -1β and Inhibiting the Aggregation of β-Amyloid Protein, Magnesium Ions Inhibit the Cognitive Decline of Amyloid Precursor Protein/Presenilin 1 Transgenic Mice (2015). *Journal of Neuroscience Research*. https://pubmed.ncbi.nlm.nih.gov/26293690/
[15] A Magtein® (Magnesium L-Threonate) Randomised Controlled Trial in Cognition (2022). *Nutrients*. DOI: 10.3390/nu14245235 | https://pubmed.ncbi.nlm.nih.gov/36558392/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786204/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Vitamin D does more than support bones. It acts as a signalling molecule that switches genes on and
Quick Read Multiple large studies show that people who drink coffee regularly have lower rates of dementia and cognitive decline.
Free guide: The research behind brain health supplements
Plus our weekly research digest — straight to your inbox.
Just leave your email address.